Celcuity (NASDAQ:CELC) Raised to Hold at Wall Street Zen

Celcuity (NASDAQ:CELC) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other research analysts have also commented on CELC. Jefferies Financial Group boosted their price target on Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, December 2nd. Needham & Company LLC reiterated a “buy” rating and issued a $122.00 target price on shares of Celcuity in a research note on Thursday. Wolfe Research reiterated an “outperform” rating and issued a $110.00 target price on shares of Celcuity in a report on Thursday, March 12th. Wells Fargo & Company started coverage on shares of Celcuity in a research report on Friday, December 12th. They set an “overweight” rating and a $126.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, January 21st. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Celcuity currently has an average rating of “Moderate Buy” and a consensus price target of $109.88.

Celcuity Stock Performance

Shares of NASDAQ:CELC opened at $106.02 on Friday. The company has a market capitalization of $4.91 billion, a price-to-earnings ratio of -27.97 and a beta of 0.38. Celcuity has a 52 week low of $7.57 and a 52 week high of $120.32. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74. The firm has a 50 day moving average of $109.49 and a 200 day moving average of $90.74.

Celcuity (NASDAQ:CELC) last posted its earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.09. On average, sell-side analysts predict that Celcuity will post -2.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Celcuity news, Director David Dalvey sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the sale, the director owned 90,000 shares of the company’s stock, valued at approximately $10,802,700. The trade was a 18.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 15.77% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Celcuity during the third quarter worth $27,000. EverSource Wealth Advisors LLC grew its holdings in shares of Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after buying an additional 319 shares during the last quarter. US Bancorp DE increased its position in shares of Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after acquiring an additional 143 shares during the period. BNP Paribas Financial Markets increased its position in shares of Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after acquiring an additional 1,167 shares during the period. Finally, Meeder Asset Management Inc. purchased a new position in Celcuity in the 4th quarter worth $42,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.